Islam et al. HCA Healthcare Journal of Medicine (2021) 2:3
https://doi.org/10.36518/2689-0216.1174

Original Research
Impact of a Meds to Beds Program on Re-presentation
Rates in Medical and Surgical Patients at a Community
Hospital
Nowshin Islam, PharmD,1 Aubrie Rafferty, PharmD, BCPS,1
Elizabeth L. Michalets, PharmD, BCPS, FCCP1

Abstract

Author affiliations are listed
at the end of this article.
Correspondence to:
Elizabeth Landrum
Michalets, PharmD, BCPS,
FCCP
Mission Hospital

Background

While the benefits of bundled transitions of care services are understood, only a limited
number of studies have analyzed the impact of a stand-alone bedside medication delivery
service on repeat hospital encounters, and those published have reported mixed results.
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Methods

A retrospective analysis was conducted in medical and surgical patients at a large community hospital. Adult patients discharged from either the cardiology, medicine, pulmonary,
orthopedic/spine surgery, or women’s surgery unit and prescribed at least one new prescription upon discharge to home between September 2015 and March 2018 were included.
The primary objective was to compare unplanned 30-day re-presentation rates in patients
who received Meds to Beds services to those who did not. The secondary objective was to
compare 30-day re-presentation rates by patient type. Re-presentation was defined as an
inpatient admission, emergency department visit, or observational encounter for any diagnosis within the six-hospital health system. Chi-square and logistic regression tests were
used to assess statistical significance, and the study was powered to detect a difference in
the primary objective.
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Results

A total of 45,546 patients were included. Of those, 4,286 received Meds to Beds services
(Intervention Group, IG) while 41,260 patients did not (Control Group, CG). Overall 30-day
re-presentation rate was not statistically different (15% IG versus 15.3% CG, OR 1.0; 95% CI
0.9-1.1; p = 0.76). However, the 30-day re-presentation rate was statistically lower for women’s surgery (12.8% IG versus 15.6%, CG p = 0.03, NNT 36) and orthopedics/spine surgery
patients (7.3% IG versus 10.2% CG, p < 0.01, NNT 34).

Conclusions

While there was no statistically significant differences in overall 30-day re-presentation
rates, there were significant reductions in two surgical patient subgroups. Avoidance of
re-presentations and generation of prescription revenue outweighed program costs.

Keywords

transitions of care; bedside medication delivery; patient readmission; hospitalization;
medication adherence; pharmaceutical services; prescriptions; medication therapy
management; disease management

Background

Due to the high frequency of unintended hospital readmissions and the associated financial
consequences, there is continued emphasis
among health systems to reduce hospital read-

missions. In 2011, 3.3 million adult readmissions
occurred in the United States with an associated hospital cost of $41.3 billion.1 The Centers of
Medicare and Medicaid Services (CMS) implemented the Medicare Hospital Readmissions
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Reduction Program, which penalizes hospitals
for readmissions. In the first year after implementation, over 2,200 hospitals were fined.2 As
a response, many health systems implemented
transitions of care services such as post-discharge phone calls, discharge medication
reconciliation and bedside medication delivery
to reduce 30-day unplanned readmissions.3
Despite these efforts, overall readmission rates
have remained relatively flat.4
Upon hospital discharge, patients may be
prescribed new medications. It is often assumed the patients will fill newly prescribed
medications and continue therapy without
interruption. Unfortunately, barriers exist that
may preclude patients from filling and obtaining prescriptions at a retail pharmacy following
hospital discharge. Barriers can include cost,
transportation challenges, hospital discharge
outside normal pharmacy hours or severity of
illness. These barriers may also be more pronounced in patients who live in rural areas. It
is estimated that approximately one-third of
patients do not fill their prescriptions.5 Furthermore, poor adherence to newly prescribed
medications has been shown to contribute
to higher readmission rates, increased health
costs and mortality in certain chronic diseases
such as asthma and diabetes.6 One approach to
ensuring patients have access to medications
at hospital discharge is through bedside delivery of the prescriptions before being discharged. A bedside medication delivery service
can mitigate some of these barriers upfront
and ensure the patient leaves with the medication in hand.
Previous studies have demonstrated that
transitions of care bundles, which include bedside discharge medication delivery, may help
decrease hospital readmissions. For example,
Christy and colleagues studied the impact of a
bundled transition of care service, which included a four-month review of discharge medications, medication counseling, delivery of medications to the bedside, scheduling a follow-up
appointment with the clinic and a follow-up
phone call at seven days. These investigators
reported that 30-day readmission rates were
5.7% in the treatment group compared to
13.8% in the control group (8.1% reduction,
p = 0.08). Although there was a reduction in
the treatment group, the study was not ade-
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quately powered to demonstrate a statistically
significant difference.7
A limited number of studies have analyzed
the impact of a stand-alone bedside medications delivery service and have reported mixed
results.8-11 Two of the studies demonstrated a
reduction in 30-day hospital readmissions.8,9
However, a larger study with over 30,000
patients that demonstrated a reduction in
30-day readmissions in medical or surgical
patients failed to show that bedside delivery of
medications at discharge was an independent
predictor of representation.10 The final study
was underpowered and did not demonstrate a
significant reduction in representations.11
This study aims to characterize further the sole
impact of a bedside medication delivery program for a larger, more diverse patient population at a large community hospital that serves
rural patients.

Methods
Design

This study is a Mission Hospital Institutional
Review Board and Research Institute approved
retrospective cohort comparison study. Data
was extracted by the research team from
electronic medical records and from reports
that track transitional activities. Patients were
evaluated over 2.5 years between September
2015 through March 2018.

Participants and Setting

Mission Hospital is an 815-bed tertiary care
community teaching hospital with approximately 150 patient discharges per day. It is the
largest hospital within a six-hospital system
that serves 18 counties in western North Carolina, many of which are rural counties. Three of
the system hospitals are critical access hospitals. The retail pharmacy located within the
hospital is open 7 AM–7 PM, Monday through
Friday and 8 AM–4 PM on Saturdays.
Patients were included in the study if they were
at least 18 years of age and discharged home
from either the cardiology, medical, pulmonary,
ortho/spine surgery or women’s surgery unit
with at least one newly prescribed discharge
medication. From that patient group, those
who opted to receive new prescriptions deliv-
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ered to their bedside before discharge comprised the intervention group (IG), and those
who did not comprised the control group (CG).
Patients discharged to a non-home disposition
such as a skilled nursing facility, rehabilitation
center or hospice were excluded. All the units
included in this study had the same degree of
clinical pharmacy coverage.

Intervention

The Meds to Beds (MTB) program at Mission
Hospital was implemented in December 2014
after receiving funding from the American
Society of Health-System Pharmacists (ASHP)
Pharmacy Practice Model Grant. Following
the grant, the service was expanded from two
patient care units to ten patient care units.
When a patient discharge order is placed by
the inpatient physician, an on-site retail pharmacy technician is paged to visit the patient.
The technician explains the program and offers
the service to the patient. If the patient agrees
to receive the service, the technician alerts
the bedside nurse and retrieves the prescriptions for bedside delivery before discharge.
The technician completes prior authorizations
and addresses other potential barriers before
prescription filling, dispensing and patient discharge. Counseling by the MTB pharmacist is
also offered to the patient. If the prescription
has any refills remaining, they are transferred
to the patient’s preferred community pharmacy. Although the program is voluntary, there
was a 97.3% patient acceptance rate when
offered the service during the first year of the
program. Common reasons for refusal of the
service were loyalty to preferred community
pharmacies and lack of ability to provide payment at the bedside before discharge.
Not all patients in the CG were offered MTB
services. For example, if they were discharged
during the weekend or after pharmacy hours,
the patients would not have been offered
MTB services. Some patients received a discharge medication reconciliation review and a
post-discharge phone call. However, since not
all patients received these additional services,
the variables were controlled for during analysis. Adherence was not assessed. Clinical
pharmacy services provided to patients in both
IG and CG were part of routine care, which
includes high-risk medication reviews, pharmacist-authorized automatic renal dosing and

IV to enteral adjustments and participation in
multidisciplinary rounds on designated units.
Discharge medication reviews were based on
specific patient criteria and discharge medication teaching was provided when the pharmacist was consulted for specific medications.
These services were provided seven days a
week on all shifts, but only a decentralized
model was used on the weekday day shift. Interaction between the clinical pharmacist and
the MTB program occurred when needed to
resolve questions about medication access or
discrepancies.

Outcome

The primary outcome of this study was a 30day re-presentation rate of the MTB intervention group compared to the control group. A
re-presentation was defined as an inpatient
admission, emergency department visit or observational status encounter for any diagnosis
within the 6-hospital health system. The secondary objective was 30-day re-presentation
rates by patient type, as defined by the specialty unit from which the patient was discharged.

Statistical Analysis

Continuous and discrete variables were presented as the mean with standard deviation or
median with interquartile range and nominal
factors as number and proportion. Demographic and index visit characteristics were
compared between the treatment and control
groups using t-test, Mann-Whitney U test or
chi-square test, as appropriate. Differences in
the outcome of the patient 30-day re-presentation to the health system were compared
between treatment groups using a chi-square
and logistic regression test. Based on previously published assessments of the 30-day
re-presentation rates at this institution, a 15%
re-presentation rate at baseline was projected.
To achieve 80% power, it was estimated that
28,006 patients were needed to demonstrate a
2% absolute reduction in re-presentation rates.
Multivariable logistic regression was used to
adjust for possible confounding factors such
as age, race, sex, insurance type, number of
disease states, encounter type, length of stay
and patient type. Since not all patients received
additional services, such as discharge medication reconciliation reviews and post-discharge
phone calls, their variables were controlled
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during analysis via multivariable logistic regression. Additionally, chi-square analysis was used
to compare differences in re-presentation rates
stratified by patient type. P-values less than
0.05 were considered to be statistically significant. All analyses were performed using SAS
software v9.4 (SAS Corporation, Cary, NC).

Results

A total of 4,286 patients received MTB services
and comprised the intervention group, while
41,260 patients were included in the control
group. A total of 845 patients were excluded
from the study due to missing data.
Demographic and clinical characteristics are
summarized in Table 1. Due to the large sample
size and disparity in the size of the two groups,
small differences were statistically significant.
The intervention group had slightly younger
patients with a median length of stay (LOS)
that was two days shorter than the control
group. The intervention group also had a higher
proportion of female and women’s surgery
Table 1. Baseline Characteristics
Patient Demographics

patients, whereas the control group had a
higher proportion of neurology patients. The
top three primary admission diagnoses among
the entire patient population based on ICD-10
codes were non-ST-elevation myocardial infarction (NSTEMI), chest pain and unstable angina.
In the intervention group, 2,057 (48%) were
medical patients, and 2,229 (52%) were surgical
patients. The control group had 26,585 (64.5%)
medical patients and 14,675 (35.5%) surgical
patients. Also, 67.6% of patients in the study
had governmental insurance, such as Medicare
or Medicaid.
More than 9,000 prescriptions were dispensed
through the MTB service over the 2.5-year
study period with an average of 3 prescriptions
per patient. The top 3 drug classes of medications dispensed were cardiac medications (e.g.,
beta-blockers), opioid analgesics and anticoagulants, which are all considered to be high-risk
medications.12 A breakdown of all drug categories dispensed through the MTB program is
displayed in Table 2.

Intervention (n=4,286)

Control (n=41,260)

P-value

Mean Age ± SD, years

60 ± 15

62 ± 16

<0.01

Gender, n (%) Female

2,523 (58.9)

21,111 (51.2)

<0.01

14 (9–19)

14 (9–20)

0.02

Median # of disease states (IQR)
Encounter Type, n (%)

<0.01
Inpatient

3,264 (76.2)

29,496 (71.5)

Observation

1,022 (23.8)

11,764 (28.5)

Discharge Unit, n (%)

<0.01
Cardiology

1,829 (42.7)

1,829 (42.7)

955 (22.3)

10,930 (26.5)

1,030 (24.0)

3,745 (9.1)

Pulmonary

430 (10.0)

4,107 (10.0)

Neurology

42 (1.0)

4,669 (11.3)

5 (2–6)

3 (2–6)

Orthopedics/Spinal Surgery
Women’s Surgery

Median Length of Stay (IQR)
Insurance, n (%)

<0.01
Governmental

2,740 (63.9)

27,886 (67.6)

Commercial

1,391 (32.5)

11,619 (28.2)

155 (3.6)

1,755 (4.3)

Self-Pay
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Table 2. Medication Categories Filled through Meds to Beds
Medication Category
Prescriptions Filled through Meds to Beds, n (%)
Cardiac Medications

2,478 (27%)

Opioid Analgesics

2,220 (24%)

Anticoagulants/ Hematopoietic Agents

924 (10%)

Gastrointestinal Agents

763 (8.3%)

Non-narcotic Analgesics

712 (7.7%)

Antibiotics

521 (5.6%)

Psychiatric Agents

327 (3.5%)

Vitamins/Supplements/Minerals

262 (2.8%)

Musculoskeletal Agents

192 (2.1%)

Corticosteroids

178 (1.9%)

Cold/Cough/Allergy

169 (1.8%)

Hypoglycemic Agents

147 (1.6%)

Bronchodilators

106 (1.2%)

Other

234 (2.5%)
Total: 9,233

The overall 30-day re-presentation rate was not
statistically different between the intervention and control groups (15% IG versus 15.3%
CG, OR 1.0; 95% CI 0.9-1.1; p = 0.76). (Figure 1)
However, a subgroup analysis based on patient type revealed that there were statistically
significant differences in the 30-day re-presentation rate in certain surgical populations. The
30-day re-presentation rate was statistically
lower in the intervention group for women’s
surgery (12.8% versus 15.6%, p = 0.03), as well
as for orthopedic and spine surgery patients
(7.3% versus 10.2%, p < 0.01). (Figure 2) For
women’s surgery, this rate represented a 2.8%
reduction (number needed to treat, NNT = 36).

In orthopedic and spine surgery patients, this
rate represented a 2.9% reduction (NNT = 34).
Differences in 30-day re-presentation rates
were not statistically different in neurology
(11.9% versus 16.3%, p = 0.44), pulmonary (25.1%
versus 22.6%, p = 0.25) or cardiology patients
(18.3% versus 16.4%, p = 0.05).
Since there was not a statistically significant
reduction in the entire population, a comprehensive cost avoidance analysis was not relevant. However, we did note that based on the
average cost of re-presentations in the surgical
subgroups who appeared to benefit from the
service, the economic benefits gained through
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Figure 1. 30-Day Health System Re-presentation Rates (N=45,546)
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Figure 2. 30-Day Re-presentation Rates by Patient Type (N=45,546).
NS=Not statistically significant
the generation of prescription revenue and
avoidance of re-presentations outweighed the
costs of providing the service.

Discussion

This study demonstrates the plausibility of
conducting a successful bedside medication
delivery service at a community hospital despite limited resources. This bedside medication delivery service eliminates the burden of
making a stop at the pharmacy after discharge
as well as cost-related barriers in obtaining
medications, and it allows medication questions to be answered with the product in hand.
All of these factors ensure that patients are
less likely to return to the hospital for unplanned presentations or have issues adhering
to new medication instructions.
Rosen and colleagues predict that patients
with poor medication adherence are also those
patients at higher risk of readmission. Patients with low and intermediate adherence
had readmission rates of 20% compared to a
readmission rate of 9.3% for patients with high
adherence (p = 0.005).13 Even for patients who
do obtain prescriptions, the risk of a preventable adverse drug event (ADE) after discharge
is significant. Forster et al. assessed the risk
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of an ADE following hospital discharge. Of the
400 patients evaluated, 45 (11.3%) developed
an ADE, of which 27% were preventable and
33% were correctable. The risk of an ADE per
prescription was highest for corticosteroids,
anticoagulants, antibiotics, analgesics and
cardiovascular medications.12 These medication classes accounted for approximately 60%
of the prescriptions filled through the MTB
program. Having these medications filled at
the hospital before discharge, with an offer to
counsel the patient on appropriate use, may
reduce the risk of preventable ADEs that can
occur from improper drug use.
As previously mentioned, a limited number of
studies have analyzed the impact of a standalone bedside medication delivery service and
reported mixed results.8-11 Lash and colleagues
studied the effects of their MTB program
in roughly 350 medical-surgical patients and
found that their service was associated with
a lower likelihood of 30-day hospital readmission (odds ratio = 0.40, 95% confidence interval 0.190, 0.843, p = 0.016).8 On a larger scale,
Comer and colleagues studied the impact of
a discharge prescription program across 15
hospital units in a large health system on 7-day
and 30-day readmission rates. The participating units included 5 medical (including 1 heart
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failure unit), 5 surgical (e.g., spine, joint replacement, urology), 3 women and children’s (including postpartum), 1 oncology, and 1 stepdown
and intensive care. They found that participation in the discharge prescription program led
to decreased odds of 7-day readmission by 20%
and 30-day readmission by 16%.9
Lam and colleagues studied the effects of a
pharmacy-driven bedside discharge medication
delivery program on 30-day hospital readmission rates in a mixture of 30,916 medical
and surgical patients at an academic medical
center. Of those, 2,253 received bedside medication delivery while 28,663 patients received
the usual care. Patients who received bedside
medication delivery were less likely to have day
30-day readmissions (10.6% vs 12.8%,
p = 0.002). However, after adjusting for differences in baseline characteristics, bedside
medication delivery was not an independent
predictor of day 30-day readmission (adjusted
odds ratio = 0.91, 95% CI 0.79–1.04, p = 0.17).10
Patel and colleagues also evaluated the impact
of a meds to beds service on 600 adult internal
medicine patients. The 30-day hospital reutilization related to their index visit was lower
in the meds-to-beds group, but the difference was not statistically significant (8.0% in
the meds-to-beds group versus 10.0% in the
control group; odds ratio, 0.78; 95% confidence
interval, 0.45–1.37), and the study was underpowered.11
The findings of this study align with those of
Lam et al. and Patel et al. since this MTB evaluation did not demonstrate an impact on overall
unplanned re-presentations. Yet certain populations of surgical patients witnessed reduced
re-presentation rates. A subgroup analysis
demonstrated statistically significant reductions in re-presentation in women’s surgery
patients and ortho/spine patients. An absolute
reduction in 30-day re-presentations of 2.8%
(NNT = 36) and 2.9% (NNT = 34) respectively
have been considered clinically significant within the health system upon previously published
transitions of care service evaluations.14 Lam’s
study also included surgical patients: 1,145
(50.8%) surgical patients in the intervention
group and 9,519 (33.2%) in the control group.
However, they failed to conduct a subgroup
analysis on this population.
Some limitations of this study include the

imbalance between the treatment and control group, resulting in marked differences in
baseline characteristics. A re-analysis using
propensity matching would mitigate this.
Another limitation is the lack of baseline acuity
measures or baseline evaluation of their risk for
re-presentation. The MTB patients had a median 2-day longer length-of-stay than the control
group, which may indicate that those patients
had more severe illnesses or were in poorer
health conditions more prone to frequent hospitalizations. This difference may have led to an
underestimation of benefit from the MTB service and partially explain why there was no difference in the overall 30-day re-presentations.
Another limitation is that the control group
included patients who were discharged on
the weekend, whereas the intervention group
did not due to limited service hours for MTB.
Weekend discharge is associated with a higher
re-presentation rate.15 Additionally, this study
only evaluated encounters within our 6-hospital
health system and was unable to account for
interactions outside of the health system that
may have occurred within 30 days of discharge.
It is also important to note that this institution’s 30-day re-presentation rate at baseline is
approximately 15%, which is comparable to the
national average.16 It is more difficult to impact
re-presentation rates that are already on par
with the rest of the nation through transitions
of care services. Finally, while this study detected a statistically significant difference in 30-day
re-presentation rates in two surgical units, it
was not powered to do so. However, assessing
the impact on specific patient populations is
useful especially when expanding the program
to target certain patient care units that may
gain more benefit than others.
In the future, consideration should be given
to an expanded comparison of patients in the
smaller rural, critical access hospitals within
the health system. Additionally, 60- and 90day re-presentation rates may be evaluated.
Since the MTB program resolves cost and prior
authorization barriers as well as transfers all
refills to the patient’s retail pharmacy of choice,
there may be more long-term reductions in
re-presentation rates. Additional considerations should also be given to an evaluation
of patient satisfaction with the MTB program
through the use of surveys or post-discharge
phone calls.
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Conclusion

Overall, the MTB service in a large community
health system did not impact overall unplanned
30-day hospital re-presentations but highlighted two surgical subgroups that may derive
benefit through avoided re-presentations.
From a quality perspective, the service ensured
patients had prescriptions in hand at discharge,
and revenue generation from prescriptions
outweighed program costs. Additional and adequately powered subgroup analyses in special
populations are warranted for future evaluation.
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